Guidelines for ATC classification and DDD assignment - WHOCC

More documents

Recommendations

Info

C CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY A Cardiac glycosides B Antiarrhythmics, class I and III C Cardiac stimulants excl. cardiac glycosides D Vasodilators used in cardiac diseases E Other cardiac preparations C02 ANTIHYPERTENSIVES A Antiadrenergic agents, centrally acting B Antiadrenergic agents, ganglion-blocking C Antiadrenergic agents, peripherally acting D Arteriolar smooth muscle, agents acting on K Other antihypertensives L Antihypertensives and diuretics in combination N Combinations of antihypertensives in ATC-gr. C02 C03 DIURETICS A Low-ceiling diuretics, thiazides B Low-ceiling diuretics, excl. thiazides C High-ceiling diuretics D Potassium-sparing agents E Diuretics and potassium-sparing agents in combination X Other diuretics C04 PERIPHERAL VASODILATORS A Peripheral vasodilators C05 VASOPROTECTIVES A Agents for treatment of hemorrhoids and anal fissures for topical use B Antivaricose therapy C Capillary stabilizing agents C07 BETA BLOCKING AGENTS A Beta blocking agents B Beta blocking agents and thiazides C Beta blocking agents and other diuretics D Beta blocking agents, thiazides and other diuretics E Beta blocking agents and vasodilators F Beta blocking agents and other antihypertensives 95
C08 CALCIUM CHANNEL BLOCKERS C Selective calcium channel blockers with mainly vascular effects D Selective calcium channel blockers with direct cardiac effects E Non-selective calcium channel blockers G Calcium channel blockers and diuretics C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM A ACE inhibitors, plain B ACE inhibitors, combinations C Angiotensin II antagonists, plain D Angiotensin II antagonists, combinations X Other agents acting on the renin-angiotensin system C10 LIPID MODIFYING AGENTS A Lipid modifying agents, plain B Lipid modifying agents, combinations 96
Page 1 and 2:
2011 WHO Collaborating Centre for D
Page 3 and 4:
ISSN 1726-4898 ISBN 978-82-8082-438
Page 5 and 6:
Previous editions: 1990: Guidelines
Page 7 and 8:
Staff of the Centre Christian Berg,
Page 9 and 10:
8 D. Principles for reviewing and c
Page 11 and 12:
I. INTRODUCTION A. History of the A
Page 13 and 14:
- To organize training courses in t
Page 15 and 16:
It is open to anyone with a legitim
Page 17 and 18:
B. Inclusion and exclusion criteria
Page 19 and 20:
If a new substance fits in both a c
Page 21 and 22:
Example: N02BA71 - acetylsalicylic
Page 23 and 24:
achieved. The harmonisation process
Page 25 and 26:
- For some groups of medicinal prod
Page 27 and 28:
For all combination products where
Page 29 and 30:
- Liquid preparations for inhalatio
Page 31 and 32:
Further reviews of DDDs After the f
Page 33 and 34:
linked to each medicinal product on
Page 35 and 36:
Use of the ATC/DDD system allows st
Page 37 and 38:
The WHO Collaborating Centre for In
Page 39 and 40:
It should be emphasised that assign
Page 41 and 42:
- If no objections are received, th
Page 43 and 44:
In order to include proposals for A
Page 45 and 46: considered as a guideline since the
Page 47 and 48: List of DDDs for combined products
Page 49 and 50: ATC SYSTEM MAIN GROUPS The main gro
Page 51 and 52: A08 ANTIOBESITY PREPARATIONS, EXCL.
Page 53 and 54: A01AC Corticosteroids for local ora
Page 55 and 56: A02AF Antacids with antiflatulents
Page 57 and 58: 56 combination will, together with
Page 59 and 60: 58 The classification at the 5th le
Page 61 and 62: A03EA Antispasmodics, psycholeptics
Page 63 and 64: A06 LAXATIVES A06A LAXATIVES 62 Lax
Page 65 and 66: A06AG Enemas 64 All enemas and laxa
Page 67 and 68: A07C ELECTROLYTES WITH CARBOHYDRATE
Page 69 and 70: A08 ANTIOBESITY PREPARATIONS, EXCL.
Page 71 and 72: A10B BLOOD GLUCOSE LOWERING DRUGS,
Page 73 and 74: 72 In A11AA04 only trace elements a
Page 75 and 76: 74 The DDDs are based on prophylaxi
Page 77 and 78: 76 classified in this group. Even c
Page 79 and 80: 78 Tonics are classified in A13. Th
Page 81 and 82: A12CC Magnesium A12CD Fluoride A12C
Page 83 and 84: A16 OTHER ALIMENTARY TRACT AND META
Page 85 and 86: B BLOOD AND BLOOD FORMING ORGANS B0
Page 87 and 88: B02 ANTIHEMORRHAGICS B02A ANTIFIBRI
Page 89 and 90: B03AA Iron bivalent, oral preparati
Page 91 and 92: 90 The DDDs are based on maintenanc
Page 93 and 94: B05C IRRIGATING SOLUTIONS 92 In thi
Page 98 and 99: C CARDIOVASCULAR SYSTEM C01 CARDIAC
Page 100 and 101: C01C CARDIAC STIMULANTS EXCL. CARDI
Page 102 and 103: C01E OTHER CARDIAC PREPARATIONS Thi
Page 104 and 105: Combinations with other antihyperte
Page 106 and 107: C02DD Nitroferricyanide derivatives
Page 108 and 109: C02LX Other antihypertensives and d
Page 110 and 111: C03BX Other low-ceiling diuretics A
Page 112 and 113: C04AC Nicotinic acid and derivative
Page 114 and 115: C05BA Heparins or heparinoids for t
Page 116 and 117: C07BG Alpha and beta blocking agent
Page 118 and 119: Combinations with ACE inhibitors ar
Page 120 and 121: C09BB ACE inhibitors and calcium ch
Page 122: C10B LIPID MODIFYING AGENTS, COMBIN
Page 125 and 126: D10 ANTI-ACNE PREPARATIONS A Anti-a
Page 127 and 128: D01AC Imidazole and triazole deriva
Page 129 and 130: D02B PROTECTIVES AGAINST UV-RADIATI
Page 131 and 132: D04AX Other antipruritics 130 This
Page 133 and 134: D06AX Other antibiotics for topical
Page 135 and 136: D07BB Corticosteroids, moderately p
Page 137 and 138: D08AD Boric acid products 136 Weak
Page 139 and 140: D10AB Preparations containing sulfu
Page 141 and 142: D11AX Other dermatologicals 140 Thi
Page 143 and 144: G GENITO URINARY SYSTEM AND SEX HOR
Page 145 and 146:
G02 OTHER GYNECOLOGICALS 144 Analge
Page 147 and 148:
146 Lisuride tablets in high streng
Page 149 and 150:
G03AD Emergency contraceptives 148
Page 151 and 152:
G03CX Other estrogens 150 Tibolone
Page 153 and 154:
152 package which is intended for o
Page 155 and 156:
G04BC Urinary concrement solvents 1
Page 158 and 159:
H SYSTEMIC HORMONAL PREPARATIONS, E
Page 160 and 161:
The DDDs are based on the treatment
Page 162 and 163:
H02A CORTICOSTEROIDS FOR SYSTEMIC U
Page 164 and 165:
H04 PANCREATIC HORMONES H04A GLYCOG
Page 166 and 167:
J ANTIINFECTIVES FOR SYSTEMIC USE J
Page 168 and 169:
J01 ANTIBACTERIALS FOR SYSTEMIC USE
Page 170 and 171:
inhibitor are classified at a separ
Page 172 and 173:
J01EA Trimethoprim and derivatives
Page 174 and 175:
J01MA Fluoroquinolones Flumequine i
Page 176 and 177:
The parenteral DDD for fosfomycin i
Page 178 and 179:
J04B DRUGS FOR TREATMENT OF LEPRA J
Page 180 and 181:
The DDD of oseltamivir is based on
Page 182 and 183:
5th level, while other monovalent v
Page 184:
J07BJ Rubella vaccines Combinations
Page 187 and 188:
L ANTINEOPLASTIC AND IMMUNOMODULATI
Page 189 and 190:
L01X OTHER ANTINEOPLASTIC AGENTS 18
Page 191 and 192:
L03AA Colony stimulating factors L0
Page 194 and 195:
M MUSCULO-SKELETAL SYSTEM M01 ANTII
Page 196 and 197:
Combinations with drugs classified
Page 198 and 199:
M01CA Quinolines The DDDs are based
Page 200 and 201:
M03AC Other quaternary ammonium com
Page 202 and 203:
M05 DRUGS FOR TREATMENT OF BONE DIS
Page 204 and 205:
N NERVOUS SYSTEM N01 ANESTHETICS A
Page 206 and 207:
N01AX Other general anesthetics Thi
Page 208 and 209:
N02A OPIOIDS This group comprises s
Page 210 and 211:
N02AG Opioids in combination with a
Page 212 and 213:
Lysine acetylsalicylate is classifi
Page 214 and 215:
The DDDs for the substances in this
Page 216 and 217:
The DDD for the combination of levo
Page 218 and 219:
N05AN Lithium The DDD is based on t
Page 220 and 221:
The DDDs are based on use of the dr
Page 222 and 223:
N06AF Monoamine oxidase inhibitors,
Page 224 and 225:
N07B DRUGS USED IN ADDICTIVE DISORD
Page 226 and 227:
P ANTIPARASITIC PRODUCTS, INSECTICI
Page 228 and 229:
The DDDs in this group are based on
Page 230 and 231:
P01C AGENTS AGAINST LEISHMANIASIS A
Page 232 and 233:
The DDD for diethylcarbamazine is b
Page 234 and 235:
R RESPIRATORY SYSTEM R01 NASAL PREP
Page 236 and 237:
The DDDs are based on the treatment
Page 238 and 239:
Antibiotics for systemic use, see J
Page 240 and 241:
The DDDs for combination products a
Page 242 and 243:
R03DA Xanthines A number of prepara
Page 244 and 245:
R05D COUGH SUPPRESSANTS, EXCL. COMB
Page 246 and 247:
The group is subdivided according t
Page 248 and 249:
S SENSORY ORGANS S01 OPHTHALMOLOGIC
Page 250 and 251:
S01AX Other antiinfectives This gro
Page 252 and 253:
S01ED Beta blocking agents Combinat
Page 254 and 255:
Hypromellose is classified in this
Page 256 and 257:
S02D OTHER OTOLOGICALS This group c
Page 258 and 259:
V VARIOUS V01 ALLERGENS A Allergens
Page 260 and 261:
V VARIOUS This group comprises many
Page 262 and 263:
The DDDs for calcium folinate, calc
Page 264 and 265:
V06 GENERAL NUTRIENTS This group co
Page 266 and 267:
V07AS Stomi equipment V07AT Cosmeti
Page 268 and 269:
( 99m Tc) exametazime labelled cell
Page 270 and 271:
classified according to such indica
Page 272 and 273:
V10 THERAPEUTIC RADIOPHARMACEUTICAL
Page 274 and 275:
List of terms: AC-system Anatomical
Page 276:
Plain preparation Preparations cont
Page 280 and 281:
Requested by: Name: Company: Addres
Page 282:
ANNEX II
Page 285 and 286:
Payment details ORDER FORM - ATC/DD
show all

Guidelines for ATC classification and DDD assignment - WHOCC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?